Cargando…

Biosimilars: Beginning a Conversation

Detalles Bibliográficos
Autores principales:	Campen, Christopher J., Mayden, Kelley D., McBride, Ali, Swit, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Harborside Press 2016
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5679036/ https://www.ncbi.nlm.nih.gov/pubmed/29152384

Ejemplares similares

Practical Strategies for Advanced Practitioners Streamlining the Integration of Oncology Biosimilar Therapies Into Practice
por: Mayden, Kelley D., et al.
Publicado: (2022)

Getting Familiar With Biosimilars
por: Mayden, Kelley D.
Publicado: (2016)

Biosimilars in the United States: Considerations for Oncology Advanced Practitioners
por: Mayden, Kelley D., et al.
Publicado: (2015)

Integrating Biosimilars Into Oncology Practice: Implications for the Advanced Practitioner
por: Campen, Christopher J.
Publicado: (2017)

A Review of the Totality of Evidence Supporting the Development of the First Adalimumab Biosimilar ABP 501
por: Markus, Richard, et al.
Publicado: (2019)

Understanding Biomarkers in Early-Stage Invasive Breast Cancer: Tools From the ASCO Clinical Guideline
por: Mayden, Kelley D.
Publicado: (2016)

Peer Review: Publication’s Gold Standard
por: Mayden, Kelley D.
Publicado: (2012)

Mind-Body Therapies: Evidence and Implications in Advanced Oncology Practice
por: Mayden,, Kelley D.
Publicado: (2012)

Case-Cohort Conundrum: Fish or No Fish?
por: Mayden, Kelley D.
Publicado: (2015)

Plagiarism’s Poison: Avoiding Scientific Misconduct
por: Mayden, Kelley D.
Publicado: (2015)

Evidence-Based Oncology Practice: Competencies for Improved Patient Outcomes
por: Mayden, Kelley D.
Publicado: (2019)

Chemotherapy Treatment Considerations in Metastatic Breast Cancer
por: Hanna, Kirollos, et al.
Publicado: (2021)

The Use of Real-World Evidence for Oral Chemotherapies in Breast Cancer
por: Hanna, Kirollos, et al.
Publicado: (2021)

Assessing Analytical and Functional Similarity of Proposed Amgen Biosimilar ABP 980 to Trastuzumab
por: Hutterer, Katariina M., et al.
Publicado: (2019)

Analytical and Functional Similarity Assessment of ABP 710, a Biosimilar to Infliximab Reference Product
por: Saleem, Ramsey, et al.
Publicado: (2020)

Analytical and functional similarity of Amgen biosimilar ABP 215 to bevacizumab
por: Seo, Neungseon, et al.
Publicado: (2018)

Economic Analysis on Adoption of Biosimilar Granulocyte Colony-Stimulating Factors in Patients With Nonmyeloid Cancer at Risk of Febrile Neutropenia Within the Oncology Care Model Framework
por: Wang, Weijia, et al.
Publicado: (2021)

Improving Health Equity: The Role of the Oncology Advanced Practitioner in Managing Implicit Bias
por: Mayden, Kelley D.
Publicado: (2021)

Functional and Nonclinical Similarity of ABP 980, a Biosimilar of Trastuzumab
por: Jassem, Shea, et al.
Publicado: (2019)

Etanercept biosimilars
por: Azevedo, Valderilio F., et al.
Publicado: (2014)

Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
por: Mysler, Eduardo, et al.
Publicado: (2021)

Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity
por: Huizinga, Tom W. J., et al.
Publicado: (2020)

Concepts and Challenges of Biosimilars in Breast Cancer: The Emergence of Trastuzumab Biosimilars
por: Uifălean, Alina, et al.
Publicado: (2018)

Improving Outcomes in HER2-Positive Breast Cancer: Analysis and Application of Evolving Data and Best Practices
por: Abraham, Jame, et al.
Publicado: (2020)

Biosimilars in dermatology
por: Mazur, Małgorzata, et al.
Publicado: (2015)

Introduction of biosimilar insulins in Europe
por: Davies, M., et al.
Publicado: (2017)

The Status of Chemotherapy in Metastatic Breast Cancer: Insights for the Advanced Practitioner
por: Hanna, Kirollos, et al.
Publicado: (2021)

The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars
por: Barbier, Liese, et al.
Publicado: (2019)

Current perspectives on biosimilars
por: Agbogbo, Frank K., et al.
Publicado: (2019)

The biosimilar pathway in the USA: An analysis of the innovator company and biosimilar company perspectives and beyond
por: Chang, Lin-Chau
Publicado: (2019)

HAPTEN-CARRIER RELATIONSHIPS OF ISOANTIGENS : A MODEL FOR IMMUNOLOGICAL MATURATION BASED ON THE CONVERSION OF HAPTENS TO CARRIERS BY ANTIBODY
por: McBride, Raymond A., et al.
Publicado: (1970)

Strengths and weaknesses of the Brazilian regulation on biosimilars: A critical view of the regulatory requirements for biosimilars in Brazil
por: de Assis, Marcos Renato, et al.
Publicado: (2018)

Beginning at the Beginning
Publicado: (1924)

Biosimilar insulins: a European perspective
por: DeVries, J H, et al.
Publicado: (2015)

The changing landscape of biosimilars in rheumatology
por: Dörner, Thomas, et al.
Publicado: (2016)

Biosimilars: potential implications for clinicians
por: Eleryan, Misty G, et al.
Publicado: (2016)

Biosimilar medicines and cost-effectiveness
por: Simoens, Steven
Publicado: (2011)

Biosimilars in ophthalmology: “Is there a big change on the horizon?”
por: Sharma, Ashish, et al.
Publicado: (2018)

Beginning Arduino
por: McRoberts, Michael
Publicado: (2013)

Beginning Arduino
por: McRoberts, Michael
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_d3c3nj23kd3oomnkapm70biv78